Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Clene Inc. - Common Stock (NQ:CLNN)

3.700 -0.030 (-0.80%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Clene Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Participation at Upcoming 36th Annual Roth Conference
Via Investor Brand Network
A Comparison Between ALS, Parkinson’s Disease
Via Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN), Subsidiary Report Positive Clinical Results of CNM-Au8 Treatment at MS Forum
Via Investor Brand Network
BioMedNewsBreaks — Clene Inc.’s (NASDAQ: CLNN) CNM-Au8 Aiming to Address Neurodegenerative Diseases from a New Angle
Via Investor Brand Network
Clene Inc. announces positive results from CNM-Au8 results from MS trial
--News Direct-- 
Via News Direct
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Statistically Significant Results from Independent Analyses of ALS Patient Data
Via Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Eyes ‘Rarely Seen’ Clinically Significant Improvement in MS Patients
Via Investor Brand Network
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Why Sony Shares Are Trading Lower By Around 6%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Sony Group Corporation (NYSE: SONY) fell during Wednesday’s session after the company reported third-quarter financial results and revised guidance above estimates and shared plans to list... 
Via Benzinga
Clene Inc. (NASDAQ: CLNN) Revolutionizes Approach to Restore Neuronal Health in Neurodegenerative Disease with CNM-Au8(R)
Via Investor Brand Network
7 Underappreciated Penny Stocks That Pack a Wallop
Although extreme speculation inherently attracts astounding risks, these underappreciated penny stocks could beat the odds. 
Via InvestorPlace
New MRI Procedure Eases Multiple Sclerosis Diagnosis
Via Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) CEO Discusses MS Trial Results During Latest Proactive Interview
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Reports ‘Unprecedented,’ Statistically Significant Long-Term Clinical Improvements for VISIONARY-MS Trial Participants with Stable Relapsing-Remitting MS
Via Investor Brand Network
Clene Inc. announces positive results from CNM-Au8 results from MS trial
Clene Inc (NASDAQ:CLNN) CEO Rob Etherington joined Steve Darling from Proactive to share news regarding the latest findings from the long-term open-label extension (LTE) of the VISIONARY-MS trial. 
Via TheNewswire.com
BioMedNewsBreaks – Clene Inc.’s (NASDAQ: CLNN) CNM-Au8 Produces ‘Significant and Very Promising Effect’ in Parkinson’s, MS Patients
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Unites Physics, Chemistry, Material Science, and Biology to Address Neurodegenerative Diseases With The Company’s Unique CNM-Au8(R) Pipeline
Via Investor Brand Network
Researchers Propose New Way to Classify Parkinson’s Disease
Via Investor Brand Network
Clene VISIONARY-MS Trial Data May Support CNM-Au8(R) as MS Treatment
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Clene Inc. (NASDAQ: CLNN) VISIONARY-MS Trial Data May Support CNM-Au8(R) as Long-Sought-After Multiple Sclerosis Treatment
Via Investor Brand Network
Ancient DNA Suggests Origins of Multiple Sclerosis in EU
Via Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Significant Positive Results from LTE VISIONARY-MS Trial
Via Investor Brand Network
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. 
Via Investor's Business Daily
New Study Highlights Role of Mitochondria in Connecting Cancer to Dietary Fat
Via Investor Brand Network
Clene Inc.’s (NASDAQ: CLNN) Phase 2 REPAIR-PD and REPAIR-MD Trials Indicate CNM-Au8(R)’s Ability to Increase Key Brain Metabolites, Supporting Advancement to Phase 3 Trials
Via Investor Brand Network
Finnish Study Suggests Exercise Plays Smaller Role in Longevity
Via Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces New Data from HEALEY ALS Platform Trial, Provides Update on ALS Clinical Development Meeting with FDA
Via Investor Brand Network
Nasdaq Gains 100 Points; CarMax Earnings Top Views
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 100 points on Thursday. The Dow traded up 0.37% to 37,218.15 while the NASDAQ rose 0.73% to 14,885.76.... 
Via Benzinga
Topics Stocks
FDA Refuses Neurology-Focused Clene's Accelerated Approval For Amyotrophic Lateral Sclerosis Treatment, Shares Fall
Clene Inc (NASDAQ: CLNN) provided an amyotrophic lateral sclerosis (ALS) regulatory update from its recent meeting with the FDA to discuss CNM-Au8 for ALS, presenting initial clinical and Neurofilament... 
Via Benzinga
Why CarMax Shares Are Trading Higher By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of CarMax, Inc. (NYSE: KMX) moved higher during Thursday’s session following better-than-expected quarterly earnings. 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback